-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, ASTZORE8n8uMacq33LWzd5Hk1e+FZy2R3s4ammaAehPh1tEeZL22Mzj057hovIua 3nnAvHg0WtHbDWk5N1Z52w== 0000950130-00-000836.txt : 20000224 0000950130-00-000836.hdr.sgml : 20000224 ACCESSION NUMBER: 0000950130-00-000836 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20000223 ITEM INFORMATION: FILED AS OF DATE: 20000223 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BECTON DICKINSON & CO CENTRAL INDEX KEY: 0000010795 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 220760120 STATE OF INCORPORATION: NJ FISCAL YEAR END: 0930 FILING VALUES: FORM TYPE: 8-K SEC ACT: SEC FILE NUMBER: 001-04802 FILM NUMBER: 551826 BUSINESS ADDRESS: STREET 1: ONE BECTON DR CITY: FRANKLIN LAKES STATE: NJ ZIP: 07417-1880 BUSINESS PHONE: 2018476800 MAIL ADDRESS: STREET 1: ONE BECTON DR CITY: FRANKLIN LAKE STATE: NJ ZIP: 07417 8-K 1 FORM 8-K SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 23, 2000 ----------------- BECTON, DICKINSON AND COMPANY - -------------------------------------------------------------------------------- (Exact name of registrant as specified in its charter) New Jersey 001-4802 22-0760120 - -------------------------------------------------------------------------------- (State or other juris- (Commission (IRS Employer Iden- diction of incorporation) File Number) tification Number) 1 Becton Drive, Franklin Lakes, New Jersey 07417-1880 - -------------------------------------------------------------------------------- (Address of principal executive offices) (Zip Code) Registrant's telephone number, including area code (201) 847-6800 -------------- N/A - -------------------------------------------------------------------------------- (Former name or former addresses if changed since last report.) Item 5. OTHER EVENTS ------------ Attached hereto as Exhibit 99, which is incorporated herein by reference, is a copy of registrant's press release dated February 23, 2000. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BECTON, DICKINSON AND COMPANY (Registrant) By: /s/ Bridget M. Healy ---------------------------- Bridget M. Healy Vice President and Secretary Date: February 23, 2000 - 2 - INDEX TO EXHIBITS ----------------- Exhibit Number Description of Exhibits ------ ----------------------- 99 Press Release issued on Febraury 23, 2000 EX-99 2 PRESS RELEASE DATED FEBRUARY 23, 2000 EXHIBIT 99 [BD LOGO APPEARS HERE] Indispensable to human health Refer To: Ronald Jasper Investor Relations (201) 847-7160 Camilla Jenkins Press Relations (201) 847-5369 BD Expects Rapid Resumption of Product Supply ---------------------------------------------- Following Voluntary Recall; Offers Alternate Product at No Charge in Interim and - -------------------------------------------------------------------------------- Confirms E.P.S. Expectations ---------------------------- Franklin Lakes, NJ - February 23, 2000 - BD (Becton, Dickinson and Company) (NYSE: BDX) today announced that it is voluntarily recalling certain manufacturing lots of the BD Insyte(R) AutoGuard(TM) shielded IV catheter. This recall only affects products from specific catalog and lot numbers. No other BD products are affected. According to the Company, the decision to recall the products was made after BD received user reports of localized skin irritation following product use. The actual percentage of products for which the Company received reports was less than .01 percent of such products used. The Company said there have been no confirmed reports of serious problems or complications. Further, the Company has not received any reports leading it to believe this irritation contributes to any serious adverse health consequences. It said it has decided to voluntarily recall the products in order to minimize additional concerns while it continues to investigate the problem. The data indicate that the problem relates to a modified formulation of the lubricant applied to certain needle gauges of Insyte AutoGuard IV catheters. All reported incidents have been with Insyte AutoGuard from those manufacturing lots that used the modified lubricant. BD has discontinued use of the modified lubricant and has resumed use of its previous lubrication which has been used since the product was introduced five years ago. BD has notified its customers and, in consideration of any inconvenience, is offering to supply them with alternate product at no charge during the period when the Insyte AutoGuard will not be available. The Company estimates that the most popular sizes and types of the product will be available regionally beginning in mid-March, with near 100% availability nationally expected by mid- April. Edward J. Ludwig, President and Chief Executive Officer said, "Our revenue expectations for the fiscal quarter ending March 31 may be reduced modestly to reflect the impact of the voluntary product recall and the earnings per share impact for the quarter should approximate $.05. This amount is expected to be substantially offset by a previously disclosed gain on the sale of a portion of the Company's holdings in an investment. Revenues for the balance of the year should not be further affected by this recall. Our strategy to help customers adopt advanced protection technologies continues to be well received by the marketplace, and we continue to be comfortable with consensus earnings per share estimates of $1.61 for the year." BD is a medical technology company that manufactures and sells a broad range of supplies, devices and systems for use by health care professionals, medical research institutions, industry and the general public. This press release may contain certain forward looking statements (as defined under Federal securities laws) regarding the company's performance, including future revenues, products and income, which are based upon current expectations of the company and involve a number of business risks and uncertainties. Actual results vary materially from anticipated results described in any forward- looking statement. Factors that could cause actual results to vary materially include, but are not limited to, competitive factors, changes in regional, national or foreign economic conditions, changes in interest or foreign currency exchange rates, delays in product introductions, year 2000 issues, and changes in health care or other governmental regulation, as well as other factors discussed herein and in the company's filings with the Securities and Exchange Commission. ### 2 -----END PRIVACY-ENHANCED MESSAGE-----